Overview

Drug-Drug Interaction Study: ASP2151 and Bupropion

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
CYP2B6 is involved in the metabolism of many drugs. So, it is important to assess in vivo the effect of ASP2151 on that enzyme to determine any possible drug interactions. The aim of this trial is to investigate the potential for interaction of ASP2151 with the CYP2B6 probe substrate bupropion.
Phase:
Phase 1
Details
Lead Sponsor:
Maruho Europe Limited
Treatments:
Bupropion